ARKG LONG prediction · arkinvest · Pending
Based on continued declines in sequencing costs, our research suggests that by 2030, the cost could fall by another order of magnitude, reaching roughly $10 per genome... AI-driven drug development has the potential to reduce time to market by roughly 40% and total development costs by about fourfold... Based on Arc's modeling, an AI-accelerated cure in its first phase of human testing, could be worth more than $2 billion per drug.
- Channel
- arkinvest
- Prediction date
- 2026-03-16
- Horizon
- 2030-12-31
- Instrument
- ARKG · LONG
- Verdict
- Pending
- Outcome
- <strong>Horizon: </strong><span data-horizon-date="2030-12-31" data-lang-zh="0">2030-12-31 · <strong>1584</strong> days remaining</span>
Source: Source · 09:42 ↗